141 related articles for article (PubMed ID: 17464771)
1. Cyclosporin a and tacrolimus (FK506) differentially alter T-cell receptor expression in vivo.
Miller JL; Ericson SG
Immunopharmacol Immunotoxicol; 2007; 29(1):105-18. PubMed ID: 17464771
[TBL] [Abstract][Full Text] [Related]
2. Concentrations of cyclosporin A and FK506 that inhibit IL-2 induction in human T cells do not affect TGF-beta1 biosynthesis, whereas higher doses of cyclosporin A trigger apoptosis and release of preformed TGF-beta1.
Minguillón J; Morancho B; Kim SJ; López-Botet M; Aramburu J
J Leukoc Biol; 2005 May; 77(5):748-58. PubMed ID: 15716327
[TBL] [Abstract][Full Text] [Related]
3. Modulation of the electrophoretic mobility of the linker for activation of T cells (LAT) by the calcineurin inhibitors CsA and FK506: LAT is a potential substrate for PKC and calcineurin signaling pathways.
Cho CS; Elkahwaji J; Chang Z; Scheunemann TL; Manthei ER; Hamawy MM
Cell Signal; 2003 Jan; 15(1):85-93. PubMed ID: 12401523
[TBL] [Abstract][Full Text] [Related]
4. Human T cell responses to human and porcine endothelial cells are highly sensitive to cyclosporin A and FK506 in vitro.
Batten P; McCormack AM; Page CS; Yacoub MH; Rose ML
Transplantation; 1999 Nov; 68(10):1552-60. PubMed ID: 10589954
[TBL] [Abstract][Full Text] [Related]
5. The mechanism of action of cyclosporin A and FK506.
Ho S; Clipstone N; Timmermann L; Northrop J; Graef I; Fiorentino D; Nourse J; Crabtree GR
Clin Immunol Immunopathol; 1996 Sep; 80(3 Pt 2):S40-5. PubMed ID: 8811062
[TBL] [Abstract][Full Text] [Related]
6. The hydroxylamine of sulfamethoxazole synergizes with FK506 and cyclosporin A, inhibiting T-cell proliferation.
Hess DA; Bird IA; Almawi WY; Rieder MJ
J Pharmacol Exp Ther; 1997 Apr; 281(1):540-8. PubMed ID: 9103542
[TBL] [Abstract][Full Text] [Related]
7. Molecular and biological actions of cyclosporin A and FK506 on T cell development and function.
Holländer GA; Bierer BE; Burakoff SJ
Transfus Sci; 1994 Sep; 15(3):207-20. PubMed ID: 10155542
[TBL] [Abstract][Full Text] [Related]
8. Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation.
Clipstone NA; Crabtree GR
Nature; 1992 Jun; 357(6380):695-7. PubMed ID: 1377362
[TBL] [Abstract][Full Text] [Related]
9. Superior T-cell suppression by rapamycin and FK506 over rapamycin and cyclosporine A because of abrogated cytotoxic T-lymphocyte induction, impaired memory responses, and persistent apoptosis.
Koenen HJ; Michielsen EC; Verstappen J; Fasse E; Joosten I
Transplantation; 2003 May; 75(9):1581-90. PubMed ID: 12792519
[TBL] [Abstract][Full Text] [Related]
10. Calcineurin mutants render T lymphocytes resistant to cyclosporin A.
Zhu D; Cardenas ME; Heitman J
Mol Pharmacol; 1996 Sep; 50(3):506-11. PubMed ID: 8794888
[TBL] [Abstract][Full Text] [Related]
11. Potentiation of CD3-induced expression of the linker for activation of T cells (LAT) by the calcineurin inhibitors cyclosporin A and FK506.
Peters D; Tsuchida M; Manthei ER; Alam T; Cho CS; Knechtle SJ; Hamawy MM
Blood; 2000 May; 95(9):2733-41. PubMed ID: 10779414
[TBL] [Abstract][Full Text] [Related]
12. Rapamycin antagonizes cyclosporin A- and tacrolimus (FK506)-mediated augmentation of linker for activation of T cell expression in T cells.
Cho CS; Chang Z; Elkahwaji J; Scheunemann TL; Manthei ER; Colburn M; Knechtle SJ; Hamawy MM
Int Immunol; 2003 Nov; 15(11):1369-78. PubMed ID: 14565935
[TBL] [Abstract][Full Text] [Related]
13. Cellular signaling mechanisms for stimulation of growth hormone secretion and growth hormone primary transcripts by immunosuppressant agents, FK506 and cyclosporin A, in cultured rat pituitary cells.
Ohye H; Sato M; Murao K; Matsubara S; Tokuda M; Takahara J
Neuroimmunomodulation; 1998; 5(6):309-17. PubMed ID: 9762012
[TBL] [Abstract][Full Text] [Related]
14. Generation of EBV-specific cytotoxic T cells that are resistant to calcineurin inhibitors for the treatment of posttransplantation lymphoproliferative disease.
Brewin J; Mancao C; Straathof K; Karlsson H; Samarasinghe S; Amrolia PJ; Pule M
Blood; 2009 Nov; 114(23):4792-803. PubMed ID: 19770360
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of CREB- and cAMP response element-mediated gene transcription by the immunosuppressive drugs cyclosporin A and FK506 in T cells.
Krüger M; Schwaninger M; Blume R; Oetjen E; Knepel W
Naunyn Schmiedebergs Arch Pharmacol; 1997 Oct; 356(4):433-40. PubMed ID: 9349628
[TBL] [Abstract][Full Text] [Related]
16. The immunosuppressive drugs cyclosporin A and FK506 inhibit calcineurin phosphatase activity and gene transcription mediated through the cAMP-responsive element in a nonimmune cell line.
Schwaninger M; Blume R; Oetjen E; Knepel W
Naunyn Schmiedebergs Arch Pharmacol; 1993 Nov; 348(5):541-5. PubMed ID: 7509460
[TBL] [Abstract][Full Text] [Related]
17. Sensitivity of whole-blood T lymphocytes in individual patients to tacrolimus (FK 506): impact of interleukin-2 mRNA expression as surrogate measure of immunosuppressive effect.
Härtel C; Schumacher N; Fricke L; Ebel B; Kirchner H; Müller-Steinhardt M
Clin Chem; 2004 Jan; 50(1):141-51. PubMed ID: 14709642
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin II signalling and calcineurin in cardiac fibroblasts: differential effects of calcineurin inhibitors FK506 and cyclosporine A.
White M; Montezano AC; Touyz RM
Ther Adv Cardiovasc Dis; 2012 Feb; 6(1):5-14. PubMed ID: 22184128
[TBL] [Abstract][Full Text] [Related]
19. Cyclosporin A, but not FK506, increases arachidonic acid release and inhibits proliferation of pituitary corticotrope tumor cells.
Pompeo A; Baldassare M; Luini A; Buccione R
Life Sci; 1999; 64(10):837-46. PubMed ID: 10096434
[TBL] [Abstract][Full Text] [Related]
20. Suppression of adult T cell leukemia-derived factor/human thioredoxin induction by FK506 and cyclosporin A: a new mechanism of immune modulation via redox control.
Furuke K; Nakamura H; Hori T; Iwata S; Maekawa N; Inamoto T; Yamaoka Y; Yodoi J
Int Immunol; 1995 Jun; 7(6):985-93. PubMed ID: 7577807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
